A clinical trial to study the effect of brain stimulation by surface magnetic coil in patients with levodopa induced abnormal movements in parkinsons disease and abnormal movements in huntingtons chorea

Evaluating the effects of repetitive transcranial magnetic stimulation in Parkinsons disease and Huntingtons disease- a pilot study

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/01/011359

Enrollment

Registered

2018-01-16

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- In patient who are ambulatory and having Parkinsons disease or Huntingtons disease Health Condition 2: G20- Parkinsons disease

Interventions

Intervention1: Repetitive transcranial magnetic stimulation(rTMS)-Real stimulation: Patients will be subjected to repetitive transcranial magnetic stimulation with a figure of 8 coil over a period of

Eligibility

Inclusion criteria

Inclusion criteria: a) PD patients diagnosed with UKPD Brain bank criteria between age group of 45-75 years with levodopa induced dyskinesia b) PD patients with stable medication for at least 30 days c) PD patients of both sexes with modified Hoen and Yahr stage-2.5-4 d) HD patients with disabling chorea (Fahn and shoulson stage 2 to 4) and non-responsive to neuroleptics

Exclusion criteria

Exclusion criteria: a) Features of Atypical Parkinsonism b) History of neurosurgery on brain c) Family (1st degree relatives) history of epilepsy d)History of psychiatric disorders (schizophrenia, schizoaffective disorder, other psychosis, claustrophobia; rapid-cycling bipolar illness, alcohol/drug abuse) within the past year

Design outcomes

Primary

Measure	Time frame
In case of parkinsonsâ??s disease, the outcome measures studied are the change in UDysR(Unified dyskinesia rating) score pre(1st day) and post rTMS(5th day). In case of Huntingtonâ??s disease, the outcome measures studied are the changes in the UHDRS(Unified huntingtons disease rating) and AIMS(Abnormal involuntary movement score) scores pre rTMS(1st day) and post rTMS(5th day) Timepoint: 1st and 5th day	—

Measure

Time frame

In case of parkinsonsâ??s disease, the outcome measures studied are the change in UDysR(Unified dyskinesia rating) score pre(1st day) and post rTMS(5th day). In case of Huntingtonâ??s disease, the outcome measures studied are the changes in the UHDRS(Unified huntingtons disease rating) and AIMS(Abnormal involuntary movement score) scores pre rTMS(1st day) and post rTMS(5th day) Timepoint: 1st and 5th day

—

Secondary

Measure	Time frame
The percentage of levodopa induced dyskinesias(LIDs) monitored with hausers motor diary over next 4 weeksTimepoint: At the end of 4 weeks	—

Countries

India

Contacts

Public ContactVarun Reddy G

AIIMS, NEW DELHI

drvinaygoyal@gmail.com01126594210

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 7, 2026